Emergent BioSolutions Inc. (NYSE:EBS) Q2 2018 Earnings Conference Call August 2, 2018 5:00 PM ET
Executives
Bob Burrows - VP, IR
Dan Abdun Nabi - CEO
Bob Kramer - President and COO
Rich Lindahl - EVP, CFO and Treasurer
Adam Havey - EVP, Business Operations
Analysts
Dana Flanders - Goldman Sachs
Brandon Folkes - Cantor Fitzgerald & Co
Yuko Oku - JPMorgan
Keay Nakae - Chardan Capital Markets
François Brisebois - Laidlaw
Boris Peaker - Cowen and Company
Lisa Springer - Singular Research
Operator
Good day, ladies and gentlemen, and welcome to the Second Quarter 2018 Emergent BioSolutions Inc Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and instructions will follow at that time. [Operator Instructions] As a reminder, this conference is being recorded.
I would now like to turn the call over to Robert Burrows, Vice President of Investor Relations. You may begin.
Bob Burrows
Thank you, Soniya, and good afternoon, everyone. Thank you for joining us today, as we discuss the operational and financial results for the second quarter and six months of 2018 for Emergent BioSolutions. As is customary, today's call is open to all participants, and in addition, the call is being recorded and is copyrighted by Emergent BioSolutions.
Participating on the call with prepared comments will be Dan Abdun Nabi, Chief Executive Officer; Bob Kramer, President and Chief Operating Officer and Rich Lindahl, our newly appointed Chief Financial Officer. Other members of the senior team are present and available during the Q&A that will follow our prepared comments.
Before beginning, I will remind everyone that during today's call or either on our prepared comments or the Q&A session, management may make projections and other forward-looking statements related to our business, future events; our prospects or future performance. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate.
